loading page

The gut-liver axis in nonalcoholic fatty liver disease: association of intestinal permeability with disease severity and treatment outcomes
  • +1
  • Yu-Pei Zhuang,
  • Yi-Ting Zhang,
  • Hao-Jie Zhong,
  • Xing-Xiang He
Yu-Pei Zhuang
The First Affiliated Hospital of Guangdong Pharmaceutical University

Corresponding Author:[email protected]

Author Profile
Yi-Ting Zhang
The First Affiliated Hospital of Guangdong Pharmaceutical University
Author Profile
Hao-Jie Zhong
The First Affiliated Hospital of Guangdong Pharmaceutical University
Author Profile
Xing-Xiang He
The First Affiliated Hospital of Guangdong Pharmaceutical University
Author Profile

Abstract

Objective To investigate the association between intestinal permeability and severity of nonalcoholic fatty liver disease (NAFLD), and the value of intestinal permeability in predicting the efficacy of metabolic therapy for NAFLD. Methods Disease severity was compared between patients with normal and elevated intestinal permeability; correlations between D-lactate and different NAFLD parameters were analyzed; and the effects of metabolic therapy on NAFLD patients with normal and elevated intestinal permeability were evaluated. Results A total of 190 patients with NAFLD were enrolled. NAFLD patients with elevated intestinal permeability had significantly higher levels of liver test parameters, liver ultrasonographic fat attenuation parameter, triglyceride, homeostasis model assessment of insulin resistance value and diamine oxidase (all P˂0.05) than NAFLD patients with normal intestinal permeability. Further, serum D-lactate levels were positively correlated with alanine transaminase, aspartate transaminase, gamma-glutamyl transpeptidase, total bilirubin, indirect bilirubin, fat attenuation parameter, triglyceride, and diamine oxidase (all P˂0.05). Moreover, NAFLD patients with elevated intestinal permeability showed less improvement in TG levels (P=0.014) after metabolic therapy. Conclusion Intestinal permeability correlates with the disease severity in patients with NAFLD. Moreover, intestinal permeability may have value for predicting the efficacy of metabolic therapy for NAFLD patients.
23 Aug 2021Submitted to International Journal of Clinical Practice
23 Aug 2021Submission Checks Completed
23 Aug 2021Assigned to Editor
03 Oct 2021Reviewer(s) Assigned
26 Oct 2021Review(s) Completed, Editorial Evaluation Pending
27 Oct 2021Editorial Decision: Revise Major
31 Jan 2022Published in International Journal of Clinical Practice volume 2022 on pages 1-7. 10.1155/2022/4797453